This paper is only available as a PDF. To read, Please Download here.
Abstract
The effectiveness of three drugs in controlling prolonged bleeding in the first year
of NORPLANTR implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day
for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib,
800 mg three times a day for 5 days) and were given orally. A control group received
a placebo (PL, one pill of lactose for 20 days). Treatment should start each time
a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers
were not aware of the drug administered. A daily record of bleeding and spotting and
of treatment intake was maintained. One-hundred-forty women completed the study period;
60 never used the prescribed treatment. Women treated with the three test drugs had
significantly fewer bleeding and spotting days during the treated month and also throughout
the study year than women using the placebo. The mean number of bleeding plus spotting
days per actually treated subject in the first year was 77, 94, 101 and 129 days for
the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help
in the management of prolonged bleeding during the first year of NORPLANTR implants use.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Norplant, reversible implant contraception.Stud Farn Plann. 1980; 11: 227-235
- International experience with NorplantR and NorplantR−2 contraceptives.Stud Fam Plann. 1988; 19: 91-94
- Long-acting contraceptive implants: an analysis of menstrual bleeding patterns.Contraception. 1978; 18: 335-365
- A three-year clinical trial with levonorgestrel Silastic implants.Contraception. 1979; 19: 557-573
- Plasma levels of d-norgestrel, estradiol and progesterone during treatment with Silastic implants contanining d-norgestrel.Contraception. 1976; 14: 81-92
- Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception.Contraception. 1978; 17: 315-328
- Hormonal changes during the first year of use of subdermal levonorgestrel implants, NorplantR.Contraception. 1984; 30: 391-405
Alvarez F, Brache V. Unpublished.
- Contraception with long-acting subdermal implants. A five-year clinical trial with Silastic covered rod implants containing levonorgestrel.Contraception. 1985; 31: 351-359
Sivin I. Unpublished.
- Contraception with d-norgestrel Silastic rods: Plasma levels of d-norgestrel and influence on the ovarian function.Contraception. 1976; 14: 551-562
- Anovulation, inadequate luteal function and poor sperm penetration in cervical mucus during prolonged use of NorplantR implants.Contraception. 1985; 31: 261-273
- Treatment with NorplantR subdermal implants inhibits sperm penetration through cervical mucus in vitro.Contraception. 1987; 36: 193-201
- Histopathology of the endometrium during continuous use of levonorgestel.in: Zatuchni GL Goldsmith A Shelton D Sciarra JJ Long-Acting Contraceptive Delivery Systems. Harper & Row Publishers, Philadelphia1984: 290-295
- Plasma progesterone levels during long-term treatment with levonorgestrel Silastic implants.Acta Endocrinol. 1982; 101: 307-311
Article info
Publication history
Accepted:
April 17,
1990
Received:
January 29,
1990
Identification
Copyright
© 1990 Published by Elsevier Inc.
